Patient Stories
Stories of Hope
Find stories of hope, told by the people who motivate us every day to continue changing the standard in cancer care.
Emily
Chuck
Celeste
Our process
Cell Therapy Explained in 5 Steps
Each cell therapy we develop is uniquely designed for each patient, harnessing the power of the immune system to target and attack cancer. Our CAR T-cell therapy manufacturing process includes these 5 steps:
STEP 1
STEP 2
STEP 3
STEP 4
STEP 5
Our Therapies
our pipeline
Our careers
Kite News
Newsroom
Recent Press Releases
-
May 15, 2025
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA -
December 09, 2024
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
Recent Company Statements
-
October 16, 2024
Kite Appoints Gallia Levy, MD, PhD, as Global Head of Clinical Development and Laura Alquist as Global Head of Technical Operations -
October 3, 2024
Kite Receives U.S. FDA Regenerative Medicine Advanced Therapy Designation for the Evaluation of Yescarta® (axicabtagene ciloleucel) CAR T-cell Therapy as First-Line Treatment for Patients with High-Risk Large B-Cell Lymphoma